You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(2197.HK)今日掛牌上市 高瓴、淡馬錫為基石投資人
格隆匯 11-05 17:36
格隆匯11月5日丨三葉草生物-B(2197.HK)今日首日掛牌上市,盤中一度漲至13.56港元,市值升至157億港元。該股IPO價格為13.38港元。高瓴、淡馬錫、前海基金等多家知名機構為基石投資人。三葉草生物是一家處於臨牀試驗階段的全球性生物技術公司,致力於為傳染性疾病以及癌症及自身免疫性疾病開發新型疫苗及生物治療候選產品。其主要產品於各治療領域的適應症分別為COVID-19、惡性腹水及強直性脊柱炎。同時,公司是COVID-19疫苗開發企業,並已創制出SCB-2019(CpG 1018/鋁佐劑)(核心產品之一)以應對SARS-CoV-2引起的COVID-19疫情。根據招股書,公司有望成為全球範圍內通過COVAX機制率先實現重組蛋白COVID-19疫苗商業化上市的公司之一。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account